Antimicrobial resistance AMR caused ~133,000 estimated deaths in 2019 in the EU, according to a Lancet report from October 2022. Responsible for the deaths of around 100 people per day in the region, AMR poses a higher threat than influenza, tuberculosis, and HIV/AIDS combined. Yet despite the mounting burden, weak commercial incentives continue to stall innovation. This has prompted the EU to acknowledge that policy gaps are stifling investment in new antimicrobials. As a solution, the European Commission has proposed transferable data exclusivity vouchers (TDEVs), a measure that has sparked a debate within the healthcare industry.
AMR costs make stronger EU antibiotic incentives harder to ignore
The Health Emergency Preparedness and Response Authority (HERA) recognizes AMR as one of the top three health threats in the region. The financial burden of AMR on EU and EEA countries amounts to nearly €11.7 billion (~US$13.3 billion) each year, as per a 2023 OECD analysis.
In addition to efforts to reduce antibiotic use, developing new antibiotics is essential to preserve the ability to treat infections, protect public health, and combat rising AMR. However, high development costs and limited return potential have discouraged investment in new antibiotics, highlighting the need for the European Commission to introduce incentives that stimulate the antibiotic innovation pipeline.
EU TDEVs try to reward antibiotics without boosting sales volume
In 2023, the European Commission put forward a recommendation to use TDEVs as a market-based tool to stimulate investment in antibiotic innovation. By offering tradable incentives decoupled from direct sales revenue, TDEVs aim to address the fundamental market failure that deters pharma companies from developing novel antibiotics.
TDEVs incentivize the development of innovative antibiotics that address significant unmet medical needs. With that, it emphasizes innovation in high-impact sectors while simultaneously imposing scientific and regulatory demands on developers.
The vouchers extend the period of data exclusivity by an additional year, likely to enable companies to earn exclusive revenue from high-revenue products without facing competition, which can enhance ROI if applied to a high-revenue drug. However, this may result in a delayed entry of generics into the market, impacting affordability.
Companies can transfer TDEVs to other pharmaceutical firms, enhancing liquidity and mitigating risks for smaller innovators. They must be used within 15 years of being granted. While they may provide industry participants with greater predictability in investment planning, they could also lead to speculative pricing.
TDEVs may look appealing to companies developing antibiotics. Still, the way they are structured could open the door to outcomes nobody intended. Costs for health systems may spiral in unpredictable ways, and companies might use the vouchers in ways that do not line up with public health priorities.
Design gaps leave TDEVs open to cost, access, and competition risks
The TDEVs model, for all its promise, carries structural risks with the potential to destabilize drug pricing and severely hamper competition and patient access across the EU’s pharmaceutical sector. Unsurprisingly, these possibilities are a major source of concern for payers, policymakers, and generic manufacturers alike.
Voucher costs could hit EU health budgets unevenly and unpredictably
The European Commission estimates that awarding one TDEV annually could add around €294 million (~US$334 million) per year to national healthcare costs, totaling roughly €4.4 billion (~US$5 billion) over 15 years. While EFPIA, a pharmaceutical industry association, notes this represents a small share of pharmaceutical budgets in most Member States (about 0.15% in countries such as the Czech Republic), costs will be unevenly distributed, with Germany, France, Italy, and Spain expected to bear half of the total burden. Overall, the financial impact per TDEV is modest for most countries but remains a significant consideration in budget planning.
On the surface, these estimates might not seem too alarming. But the actual cost of a TDEV is unpredictable and hinges entirely on which drug gets the exclusivity extension. A 2020 cost-benefit study affiliated with the Antimicrobial Resistance Center in Norway analyzed scenarios where blockbuster drugs such as AbbVie’s Humira or Pfizer’s Lyrica received vouchers, projecting potential costs to healthcare systems exceeding US$3 billion. This indicates that the true cost of a TDEV could potentially impose high, unpredictable costs, especially if applied to high-revenue drugs. This raised real concerns about transparency, fairness, and the need for stronger safeguards.
TDEVs are given to a company that successfully develops a new antibiotic. The crucial point, however, is that the voucher does not need to be applied to that antibiotic. Instead, the company can use it for any other drug in its portfolio, such as a high-revenue, non-antibiotic drug. It can also sell the voucher to another pharmaceutical company, which may then apply it to one of its blockbuster drugs. As a result, the health system ends up paying more, not because of the antibiotic itself, but because a completely unrelated, expensive drug stays on the market without generic competition. This situation creates a risk of distorted incentives and financial pressure on health systems.
“We do not know what kind of cost this (TDEVs) will create for health insurance systems. These (TDEVs) are motivating for the industry but opaque for the health insurance system. In general, the voucher system is not bad in itself, but we need to work out who bears the cost of it. The proposal may mean that only some member states’ health systems will pay the cost of the voucher. Work is already underway to modify it, including at the working group level. We need to find a balanced approach.” – Jakub Dvořáček, Deputy Health Minister of the Czech Republic, 2023
Bankruptcy risk can leave TDEV-backed antibiotics off the market
TDEVs incentivize development without tying the reward to the actual clinical or public health value of the antibiotic. The framework does not impose strict requirements to ensure the drug’s market availability. Once the voucher is granted, there is no obligation for the company to distribute the antibiotic in all EU countries, sustain its market presence, or ensure a reliable supply.
If a company goes bankrupt or simply changes strategic direction, the antibiotic may never reach patients or could be pulled from the market shortly after launch. This scenario reveals a fundamental flaw in the system. From a public health standpoint, the entire incentive fails to achieve its primary goal.
Big Pharma can use TDEVs to extend non-antibiotic monopolies
TDEVs aim to boost antibiotic innovation, but large pharmaceutical companies can use them to extend monopolies on unrelated blockbuster drugs. SMEs develop most antibiotics but often lack the resources to commercialize them. As a result, they sell the vouchers (often below value) to big companies. These larger firms then typically apply the voucher to one of their own blockbuster drugs, delaying the entry of generics and restricting competition, without adding real innovation.
A relevant example of the threat comes from 2024, when the European Commission fined Teva €462 million for abusing the divisional patent system to unfairly delay generic competition for its multiple sclerosis drug, Copaxone. While this case did not involve TDEVs, it shows how companies can manipulate exclusivity mechanisms to protect profits at the expense of access. Without strong safeguards, TDEVs can become a profit-maximization tool rather than a public health incentive.
Related reading:
Antibiotic Pipeline Collapse Deepens as AMR Market Failure Resists a Cure
Generic competition faces delays when TDEVs extend exclusivity
In Europe, generics account for about 70% of all treatments, yet they bring in just 19% of market value. That gap shows how central they are to keeping medicines affordable.
However, TDEVs risk disrupting this balance. Granting TDEVs to already commercially successful blockbuster drugs would unfairly disadvantage generics by delaying their market entry, thereby weakening competition and limiting both the availability and affordability of treatments in vital therapeutic areas. A 2018 study by Copenhagen Economics underscores the importance of timely generic entry, showing that prices of originator drugs drop by ~40% on average once generics enter the market.
The vouchers could distort the market by creating unpredictability around exclusivity periods. This uncertainty may discourage generics manufacturers from investing in lower-cost alternatives, keeping prices artificially high and limiting patient access.
“TDEVs could also delay the entry of generic medicines into the market. I am still not convinced of the transparency of the transferable exclusivity vouchers, and hence I deleted the chapter. Proposing such a measure without requirements and conditionality for a company to guarantee supply of the antimicrobial from which the voucher was awarded is inconceivable from my perspective.” – Tiemo Wölken, Member of European Parliament, Germany, 2023
Innovation diversity narrows when TDEVs reward safer antibiotic bets
A TDEV rewards just one antibiotic innovation, but the voucher, as such, can be used on any drug. This structure could easily push companies to prioritize developing safer, lower-risk antibiotics, not necessarily to meet a medical need, but primarily to secure the valuable voucher. This could deter investment in more risky or genuinely innovative antibiotic strategies. Over time, this may constrict the innovation pipeline and impede breakthroughs.
By extending the exclusivity of existing drugs, TDEVs may deter the creation of truly innovative and novel antimicrobials. Companies might be inclined to develop “me-too” drugs that closely resemble drugs already on the market, as these options carry a lower risk and a more reliable route to market.
SME antibiotic developers face added TDEV costs and complexity
The vouchers create complexity with their eligibility guidelines, transfer systems, and evaluations. This additional regulatory and administrative burden could require more time and financial resources, which is especially problematic for smaller companies that have limited means. It may also impede market entry and dampen investment enthusiasm.
Explore more analysis on EOS Implicium
Investor confidence suffers if TDEVs stay complex and uncertain
The vouchers aim to support antibiotic innovation, but if investors see them as too complicated or financially risky, they might be unwilling to invest in antibiotic R&D, despite the existing incentive. Venture capital and biotech investors are already dealing with long timelines and high risk in the antibiotic field. An incentive that itself appears complicated or financially uncertain could easily make them more cautious. The likely outcome is that capital goes to other therapeutic areas promising more stable and predictable returns. That would weaken private investment in antibiotic R&D and compromise the policy’s intention to stimulate innovation.
EOS Implic-Action: Tighter TDEV rules decide who gains from AMR incentives
TDEVs came with a clear purpose to support antibiotic development in a market that does not motivate sufficient innovation. But when left too open-ended, tools such as these can be used in ways that miss their original goal. What starts as a public health incentive may become a commercial lever for those best equipped to exploit it (typically powerful market leaders).
Large pharmaceutical companies often take the lead in this environment. For pharma enterprises, this can help create clearer and more predictable valuations, which in turn lowers risks. Instead of health systems facing unexpected expenses, the company purchasing the TDEVs would pay a set amount. This arrangement gives both parties a clearer view of costs and rewards. It makes it easier for companies to plan their investments and avoid financial surprises. While these features simplify investment decisions, in practice, they primarily benefit companies that already possess the resources, legal support, and regulatory experience to navigate complex systems such as tDEVs.
Clear TDEV limits can keep AMR rewards tied to antibiotic value
Some proposed policy features could better align the incentives system. They could allow the market to play a role in setting a fair and efficient exclusivity period, based on what companies are willing to accept in return for fixed payments. The idea would be to introduce self-limiting mechanisms. Shorter exclusivity in exchange for greater certainty upfront. However, even these will need clear boundaries if they are to avoid becoming just another pricing strategy.
For smaller developers, the situation looks different. Few can afford long regulatory paths or hold out for the full commercial cycle. Vouchers may help them in theory, but in practice, companies often sell rather than leverage them. The vouchers should add predictability. In reality, they can stretch exclusivity on unrelated drugs, keeping generics out and driving up prices.
If regulators fail to introduce tighter eligibility rules, clarify the link between the voucher and antibiotic value, and set stronger limits on where companies can apply the voucher, large pharmaceutical companies could primarily use TDEVs to defend their blockbuster drugs that have no connection to antibiotics. This would harm competition and put smaller innovators at a disadvantage. It could steer the market towards a scenario where fewer players hold more power. This, in turn, would stall the development and innovation of new antibiotics. A more defined and stronger TDEV framework is vital for preserving a fair competitive environment and stimulating true innovation.